Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC
Background and Aims Chimeric antigen receptor engineered T cells (CARTs) for HCC and other solid tumors are not as effective as they are for blood cancers. CARTs may lose function inside tumors due to persistent antigen engagement. The aims of this study are to develop low‐affinity monoclonal antibo...
Saved in:
| Published in | Hepatology (Baltimore, Md.) Vol. 76; no. 2; pp. 330 - 344 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wolters Kluwer Health, Inc
01.08.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background and Aims
Chimeric antigen receptor engineered T cells (CARTs) for HCC and other solid tumors are not as effective as they are for blood cancers. CARTs may lose function inside tumors due to persistent antigen engagement. The aims of this study are to develop low‐affinity monoclonal antibodies (mAbs) and low‐avidity CARTs for HCC and to test the hypothesis that low‐avidity CARTs can resist exhaustion and maintain functions in solid tumors, generating durable antitumor effects.
Methods and Results
New human glypican‐3 (hGPC3) mAbs were developed from immunized mice. We obtained three hGPC3‐specific mAbs that stained HCC tumors, but not the adjacent normal liver tissues. One of them, 8F8, bound an epitope close to that of GC33, the frequently used high‐affinity mAb, but with approximately 17‐fold lower affinity. We then compared the 8F8 CARTs to GC33 CARTs for their in vitro function and in vivo antitumor effects. In vitro, low‐avidity 8F8 CARTs killed both hGPC3high and hGPC3low HCC tumor cells to the same extent as high‐avidity GC33 CARTs. 8F8 CARTs expanded and persisted to a greater extent than GC33 CARTs, resulting in durable responses against HCC xenografts. Importantly, compared with GC33 CARTs, there were 5‐fold more of 8F8‐BBz CARTs in the tumor mass for a longer period of time. Remarkably, the tumor‐infiltrating 8F8 CARTs were less exhausted and apoptotic, and more functional than GC33 CARTs.
Conclusion
The low‐avidity 8F8‐BBz CART resists exhaustion and apoptosis inside tumor lesions, demonstrating a greater therapeutic potential than high‐avidity CARTs. |
|---|---|
| AbstractList | Background and AimsChimeric antigen receptor engineered T cells (CARTs) for HCC and other solid tumors are not as effective as they are for blood cancers. CARTs may lose function inside tumors due to persistent antigen engagement. The aims of this study are to develop low‐affinity monoclonal antibodies (mAbs) and low‐avidity CARTs for HCC and to test the hypothesis that low‐avidity CARTs can resist exhaustion and maintain functions in solid tumors, generating durable antitumor effects.Methods and ResultsNew human glypican‐3 (hGPC3) mAbs were developed from immunized mice. We obtained three hGPC3‐specific mAbs that stained HCC tumors, but not the adjacent normal liver tissues. One of them, 8F8, bound an epitope close to that of GC33, the frequently used high‐affinity mAb, but with approximately 17‐fold lower affinity. We then compared the 8F8 CARTs to GC33 CARTs for their in vitro function and in vivo antitumor effects. In vitro, low‐avidity 8F8 CARTs killed both hGPC3high and hGPC3low HCC tumor cells to the same extent as high‐avidity GC33 CARTs. 8F8 CARTs expanded and persisted to a greater extent than GC33 CARTs, resulting in durable responses against HCC xenografts. Importantly, compared with GC33 CARTs, there were 5‐fold more of 8F8‐BBz CARTs in the tumor mass for a longer period of time. Remarkably, the tumor‐infiltrating 8F8 CARTs were less exhausted and apoptotic, and more functional than GC33 CARTs.ConclusionThe low‐avidity 8F8‐BBz CART resists exhaustion and apoptosis inside tumor lesions, demonstrating a greater therapeutic potential than high‐avidity CARTs. Background and Aims Chimeric antigen receptor engineered T cells (CARTs) for HCC and other solid tumors are not as effective as they are for blood cancers. CARTs may lose function inside tumors due to persistent antigen engagement. The aims of this study are to develop low‐affinity monoclonal antibodies (mAbs) and low‐avidity CARTs for HCC and to test the hypothesis that low‐avidity CARTs can resist exhaustion and maintain functions in solid tumors, generating durable antitumor effects. Methods and Results New human glypican‐3 (hGPC3) mAbs were developed from immunized mice. We obtained three hGPC3‐specific mAbs that stained HCC tumors, but not the adjacent normal liver tissues. One of them, 8F8, bound an epitope close to that of GC33, the frequently used high‐affinity mAb, but with approximately 17‐fold lower affinity. We then compared the 8F8 CARTs to GC33 CARTs for their in vitro function and in vivo antitumor effects. In vitro, low‐avidity 8F8 CARTs killed both hGPC3high and hGPC3low HCC tumor cells to the same extent as high‐avidity GC33 CARTs. 8F8 CARTs expanded and persisted to a greater extent than GC33 CARTs, resulting in durable responses against HCC xenografts. Importantly, compared with GC33 CARTs, there were 5‐fold more of 8F8‐BBz CARTs in the tumor mass for a longer period of time. Remarkably, the tumor‐infiltrating 8F8 CARTs were less exhausted and apoptotic, and more functional than GC33 CARTs. Conclusion The low‐avidity 8F8‐BBz CART resists exhaustion and apoptosis inside tumor lesions, demonstrating a greater therapeutic potential than high‐avidity CARTs. Chimeric antigen receptor engineered T cells (CARTs) for HCC and other solid tumors are not as effective as they are for blood cancers. CARTs may lose function inside tumors due to persistent antigen engagement. The aims of this study are to develop low-affinity monoclonal antibodies (mAbs) and low-avidity CARTs for HCC and to test the hypothesis that low-avidity CARTs can resist exhaustion and maintain functions in solid tumors, generating durable antitumor effects. New human glypican-3 (hGPC3) mAbs were developed from immunized mice. We obtained three hGPC3-specific mAbs that stained HCC tumors, but not the adjacent normal liver tissues. One of them, 8F8, bound an epitope close to that of GC33, the frequently used high-affinity mAb, but with approximately 17-fold lower affinity. We then compared the 8F8 CARTs to GC33 CARTs for their in vitro function and in vivo antitumor effects. In vitro, low-avidity 8F8 CARTs killed both hGPC3 and hGPC3 HCC tumor cells to the same extent as high-avidity GC33 CARTs. 8F8 CARTs expanded and persisted to a greater extent than GC33 CARTs, resulting in durable responses against HCC xenografts. Importantly, compared with GC33 CARTs, there were 5-fold more of 8F8-BBz CARTs in the tumor mass for a longer period of time. Remarkably, the tumor-infiltrating 8F8 CARTs were less exhausted and apoptotic, and more functional than GC33 CARTs. The low-avidity 8F8-BBz CART resists exhaustion and apoptosis inside tumor lesions, demonstrating a greater therapeutic potential than high-avidity CARTs. Chimeric antigen receptor engineered T cells (CARTs) for HCC and other solid tumors are not as effective as they are for blood cancers. CARTs may lose function inside tumors due to persistent antigen engagement. The aims of this study are to develop low-affinity monoclonal antibodies (mAbs) and low-avidity CARTs for HCC and to test the hypothesis that low-avidity CARTs can resist exhaustion and maintain functions in solid tumors, generating durable antitumor effects.BACKGROUND AND AIMSChimeric antigen receptor engineered T cells (CARTs) for HCC and other solid tumors are not as effective as they are for blood cancers. CARTs may lose function inside tumors due to persistent antigen engagement. The aims of this study are to develop low-affinity monoclonal antibodies (mAbs) and low-avidity CARTs for HCC and to test the hypothesis that low-avidity CARTs can resist exhaustion and maintain functions in solid tumors, generating durable antitumor effects.New human glypican-3 (hGPC3) mAbs were developed from immunized mice. We obtained three hGPC3-specific mAbs that stained HCC tumors, but not the adjacent normal liver tissues. One of them, 8F8, bound an epitope close to that of GC33, the frequently used high-affinity mAb, but with approximately 17-fold lower affinity. We then compared the 8F8 CARTs to GC33 CARTs for their in vitro function and in vivo antitumor effects. In vitro, low-avidity 8F8 CARTs killed both hGPC3high and hGPC3low HCC tumor cells to the same extent as high-avidity GC33 CARTs. 8F8 CARTs expanded and persisted to a greater extent than GC33 CARTs, resulting in durable responses against HCC xenografts. Importantly, compared with GC33 CARTs, there were 5-fold more of 8F8-BBz CARTs in the tumor mass for a longer period of time. Remarkably, the tumor-infiltrating 8F8 CARTs were less exhausted and apoptotic, and more functional than GC33 CARTs.METHODS AND RESULTSNew human glypican-3 (hGPC3) mAbs were developed from immunized mice. We obtained three hGPC3-specific mAbs that stained HCC tumors, but not the adjacent normal liver tissues. One of them, 8F8, bound an epitope close to that of GC33, the frequently used high-affinity mAb, but with approximately 17-fold lower affinity. We then compared the 8F8 CARTs to GC33 CARTs for their in vitro function and in vivo antitumor effects. In vitro, low-avidity 8F8 CARTs killed both hGPC3high and hGPC3low HCC tumor cells to the same extent as high-avidity GC33 CARTs. 8F8 CARTs expanded and persisted to a greater extent than GC33 CARTs, resulting in durable responses against HCC xenografts. Importantly, compared with GC33 CARTs, there were 5-fold more of 8F8-BBz CARTs in the tumor mass for a longer period of time. Remarkably, the tumor-infiltrating 8F8 CARTs were less exhausted and apoptotic, and more functional than GC33 CARTs.The low-avidity 8F8-BBz CART resists exhaustion and apoptosis inside tumor lesions, demonstrating a greater therapeutic potential than high-avidity CARTs.CONCLUSIONThe low-avidity 8F8-BBz CART resists exhaustion and apoptosis inside tumor lesions, demonstrating a greater therapeutic potential than high-avidity CARTs. |
| Author | Hussein, Mohamed S. He, Yukai Jiang, Xiaotao Mao, Rui Kehinde‐Ige, Mercy Sadek, Ramses Qiu, Xiangguo Peng, Yibing Caraballo Galva, Leidy D. Brody, Pierce Zhang, Huajun He, Aiwu Ruth Shi, Huidong |
| AuthorAffiliation | 4 Lombardi Cancer Center, Georgetown University, Washington, District of Columbia, USA 3 Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada 1 Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, Georgia, USA 2 Department of Medicine, Medical College of Georgia, Augusta University, Augusta, Georgia, USA |
| AuthorAffiliation_xml | – name: 2 Department of Medicine, Medical College of Georgia, Augusta University, Augusta, Georgia, USA – name: 4 Lombardi Cancer Center, Georgetown University, Washington, District of Columbia, USA – name: 3 Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada – name: 1 Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, Georgia, USA |
| Author_xml | – sequence: 1 givenname: Leidy D. orcidid: 0000-0003-4263-8419 surname: Caraballo Galva fullname: Caraballo Galva, Leidy D. organization: Augusta University – sequence: 2 givenname: Xiaotao orcidid: 0000-0001-7571-1593 surname: Jiang fullname: Jiang, Xiaotao organization: Augusta University – sequence: 3 givenname: Mohamed S. orcidid: 0000-0001-9277-713X surname: Hussein fullname: Hussein, Mohamed S. organization: Augusta University – sequence: 4 givenname: Huajun surname: Zhang fullname: Zhang, Huajun organization: University of Manitoba – sequence: 5 givenname: Rui surname: Mao fullname: Mao, Rui organization: Augusta University – sequence: 6 givenname: Pierce surname: Brody fullname: Brody, Pierce organization: Augusta University – sequence: 7 givenname: Yibing surname: Peng fullname: Peng, Yibing organization: Augusta University – sequence: 8 givenname: Aiwu Ruth surname: He fullname: He, Aiwu Ruth organization: Georgetown University – sequence: 9 givenname: Mercy surname: Kehinde‐Ige fullname: Kehinde‐Ige, Mercy organization: Augusta University – sequence: 10 givenname: Ramses surname: Sadek fullname: Sadek, Ramses organization: Augusta University – sequence: 11 givenname: Xiangguo surname: Qiu fullname: Qiu, Xiangguo organization: University of Manitoba – sequence: 12 givenname: Huidong orcidid: 0000-0003-1137-3390 surname: Shi fullname: Shi, Huidong organization: Augusta University – sequence: 13 givenname: Yukai orcidid: 0000-0001-7636-5549 surname: He fullname: He, Yukai email: yhe@augusta.edu organization: Augusta University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34897774$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kc1uEzEUhS1URNPCghdAltiUxbS253-FqlEhSBUgVNbWHc914sqxgz2Tkh2P0Gfsk-CQUkElWFm6_u7ROfcckQPnHRLykrNTzpg4W-L6NBeibp-QGS9FneV5yQ7IjImaZS3P20NyFOM1Y6wtRPOMHOZF09Z1XcxI_Og3aKn1N3c_bmFjBjNu6cJu10aBS6OcxjUqo42i3fmXq0gDRhNHit-XMMXReEfBDXSFg4ER6TAF6C2m2WjGaeUDRa1RjZHCAoxLi_Oue06earARX9y_x-Tru4urbp5dfnr_oTu_zFSZ_GW87euaN001iFYrFFUJUDVQKN43QrO26kGxgpcMe1GoAXRKpCumc6wYMAb5MXm7111PfTKo0I0BrFwHs4KwlR6M_PvHmaVc-I3krKyasmBJ4eReIfhvE8ZRrkxUaC049FOUokoXLeuci4S-foRe-ym4lC9R7e7yZVEn6tWflh68_C4kAW_2gAo-xoD6AeFM7sqWqWz5q-zEnj1ilRlh10lKY-z_Nm6Mxe2_peX84vN-4yfJHb3u |
| CitedBy_id | crossref_primary_10_1017_erm_2021_32 crossref_primary_10_1038_s41467_024_47799_z crossref_primary_10_3389_fimmu_2022_830292 crossref_primary_10_1007_s10238_023_01015_2 crossref_primary_10_3389_fimmu_2023_1258156 crossref_primary_10_5939_sjws_240003 crossref_primary_10_1186_s12943_023_01886_9 crossref_primary_10_1016_j_ymthe_2025_01_035 crossref_primary_10_1186_s12943_024_01952_w crossref_primary_10_3390_cancers14153618 crossref_primary_10_3390_ijms26031079 crossref_primary_10_3389_fimmu_2022_1032403 crossref_primary_10_1002_jbt_70091 crossref_primary_10_3389_fimmu_2023_1114770 crossref_primary_10_1172_JCI163291 crossref_primary_10_1016_j_ijbiomac_2025_139829 crossref_primary_10_34133_adi_0043 |
| Cites_doi | 10.3748/wjg.v22.i1.275 10.3389/fimmu.2017.01597 10.1002/hep.29844 10.4049/jimmunol.180.10.7028 10.1158/1078-0432.CCR-18-2559 10.1016/j.jgg.2020.01.002 10.1158/2326-6066.CIR-14-0200 10.1158/1078-0432.CCR-13-0330 10.1016/j.molmed.2015.05.005 10.1158/0008-5472.CAN-15-0159 10.1038/mt.2016.63 10.1038/s41591-019-0564-6 10.1038/modpathol.3800436 10.1016/j.jim.2007.09.017 10.1056/NEJMra1706169 10.1126/science.abc6952 10.1016/j.ccell.2018.03.012 10.1158/1078-0432.CCR-14-1170 10.1158/0008-5472.CAN-08-1973 10.1038/nm.3838 10.1158/1078-0432.CCR-19-3259 10.1093/nar/gku1056 10.1186/s12967-020-02462-1 10.4049/jimmunol.174.6.3808 10.1016/j.ymthe.2017.04.017 10.1038/nature22367 10.4161/mabs.20933 10.1002/hep.26893 10.1016/j.bbrc.2008.11.033 10.1038/s41598-017-14749-3 10.4049/jimmunol.1402346 10.1016/j.ebiom.2020.102931 10.1038/ni.2035 10.1309/HCQWPWD50XHD2DW6 10.1158/1078-0432.CCR-19-1835 10.1053/j.gastro.2020.02.011 10.1038/s41467-020-17970-3 10.4049/jimmunol.178.7.4650 10.1038/ncomms7536 10.1158/2326-6066.CIR-17-0211 10.1038/s41591-019-0549-5 10.1038/s41419-018-0278-6 10.1038/gt.2010.91 10.1038/leu.2016.35 |
| ContentType | Journal Article |
| Copyright | 2021 American Association for the Study of Liver Diseases. 2022 American Association for the Study of Liver Diseases. |
| Copyright_xml | – notice: 2021 American Association for the Study of Liver Diseases. – notice: 2022 American Association for the Study of Liver Diseases. |
| DBID | AAYXX CITATION NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 5PM |
| DOI | 10.1002/hep.32279 |
| DatabaseName | CrossRef PubMed Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1527-3350 |
| EndPage | 344 |
| ExternalDocumentID | PMC10568540 34897774 10_1002_hep_32279 HEP32279 |
| Genre | article Journal Article |
| GroupedDBID | --- --K .3N .55 .GA .GJ .Y3 05W 0R~ 10A 186 1B1 1CY 1L6 1OB 1OC 1ZS 1~5 24P 31~ 33P 3O- 3SF 3WU 4.4 4G. 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AANHP AAONW AAQFI AAQQT AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABIJN ABLJU ABMAC ABOCM ABPVW ABWVN ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACLDA ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADMUD ADNMO ADOZA ADXAS ADZMN ADZOD AECAP AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFGKR AFPWT AFUWQ AFZJQ AHMBA AIACR AIURR AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD F00 F01 F04 F5P FD8 FDB FEDTE FGOYB FUBAC G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IHE IX1 J0M J5H JPC KBYEO KQQ LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 M65 MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB NQ- O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K R2- RGB RIG RIWAO RJQFR ROL RPZ RWI RX1 RYL SEW SSZ SUPJJ TEORI UB1 V2E V9Y W2D W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WXI X7M XG1 XV2 ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX ABJNI ACZKN ADSXY AEFGJ AFNMH AGQPQ AGXDD AHQVU AIDQK AIDYY CITATION MEWTI WXSBR ACIJW NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 5PM |
| ID | FETCH-LOGICAL-c5489-19b771886d29fce265aa68a4c1b82f096bac04150eb24cdaf777f60f3e60a00a3 |
| IEDL.DBID | DR2 |
| ISSN | 0270-9139 1527-3350 |
| IngestDate | Thu Aug 21 18:35:43 EDT 2025 Fri Jul 11 10:26:38 EDT 2025 Wed Aug 13 08:33:35 EDT 2025 Wed Feb 19 02:27:12 EST 2025 Wed Aug 27 16:26:50 EDT 2025 Thu Apr 24 23:03:49 EDT 2025 Wed Jan 22 16:25:11 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | 2021 American Association for the Study of Liver Diseases. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5489-19b771886d29fce265aa68a4c1b82f096bac04150eb24cdaf777f60f3e60a00a3 |
| Notes | Funding information Supported by Augusta University start‐up fund Leidy D. Caraballo Galva, Xiaotao Jiang, Mohamed S. Hussein, and Huajun Zhang contributed equally to this work. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Present address Xiaotao Jiang, Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China AUTHOR CONTRIBUTIONS Huajun Zhang, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China YH conceive the hypothesis and is in charge of the overall experimental design, experiments, and data analysis and summary. YH, XJ, LDCG, MSH, and HZ designed and conducted the majority of the experiments, analyzed and summarized the data. HZ and XQ did the affinity study. ARH conducted IHC staining on liver tissues and analyzed data. RM, PB, and YP prepared the CAR lentivectors and helped conducted the in vivo animal studies. MK-I and HS performed the RNAseq analysis. RS did the statistical analysis. YH, XJ, LDCG, MSH, and HZ wrote the manuscript. |
| ORCID | 0000-0001-9277-713X 0000-0001-7571-1593 0000-0003-1137-3390 0000-0003-4263-8419 0000-0001-7636-5549 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/10568540 |
| PMID | 34897774 |
| PQID | 2690094547 |
| PQPubID | 996352 |
| PageCount | 15 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10568540 proquest_miscellaneous_2609457312 proquest_journals_2690094547 pubmed_primary_34897774 crossref_primary_10_1002_hep_32279 crossref_citationtrail_10_1002_hep_32279 wiley_primary_10_1002_hep_32279_HEP32279 |
| PublicationCentury | 2000 |
| PublicationDate | 20220800 |
| PublicationDateYYYYMMDD | 2022-08-01 |
| PublicationDate_xml | – month: 08 year: 2022 text: 20220800 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Hepatology (Baltimore, Md.) |
| PublicationTitleAlternate | Hepatology |
| PublicationYear | 2022 |
| Publisher | Wolters Kluwer Health, Inc |
| Publisher_xml | – name: Wolters Kluwer Health, Inc |
| References | 2017; 6 2017; 7 2017; 8 2015; 6 2005; 174 2015; 3 2017; 25 2010; 17 2015; 75 2008; 329 2020; 369 2016; 30 2008; 129 2020; 58 2011; 12 2020; 11 2021; 71 2009; 378 2018; 68 2014; 20 2020; 18 2013; 19 2018; 6 2008; 180 2021; 13 2018; 9 2007; 178 2015; 194 2018; 379 2015; 21 2019; 25 2015; 43 2014; 59 2020; 26 2020; 47 2008; 68 2021; 372 2020; 158 2018; 33 2012; 4 2005; 18 2016; 24 2017; 545 2016; 22 (hep32279-bib-0002-20250824) 2015; 21 (hep32279-bib-0030-20250824) 2020; 369 (hep32279-bib-0036-20250824) 2007; 178 (hep32279-bib-0046-20250824) 2020; 26 (hep32279-bib-0033-20250824) 2015; 43 (hep32279-bib-0043-20250824) 2015; 3 (hep32279-bib-0001-20250824) 2021; 71 (hep32279-bib-0039-20250824) 2015; 6 (hep32279-bib-0038-20250824) 2019; 25 (hep32279-bib-0006-20250824) 2011; 12 (hep32279-bib-0012-20250824) 2019; 25 (hep32279-bib-0027-20250824) 2017; 7 (hep32279-bib-0008-20250824) 2010; 17 (hep32279-bib-0014-20250824) 2013; 19 (hep32279-bib-0017-20250824) 2019; 25 (hep32279-bib-0044-20250824) 2021; 13 (hep32279-bib-0035-20250824) 2016; 22 (hep32279-bib-0047-20250824) 2017; 8 (hep32279-bib-0032-20250824) 2014; 59 (hep32279-bib-0020-20250824) 2020; 18 (hep32279-bib-0028-20250824) 2020; 11 (hep32279-bib-0041-20250824) 2005; 18 (hep32279-bib-0016-20250824) 2018; 6 (hep32279-bib-0023-20250824) 2012; 4 (hep32279-bib-0045-20250824) 2021; 372 (hep32279-bib-0018-20250824) 2014; 20 (hep32279-bib-0026-20250824) 2015; 75 (hep32279-bib-0031-20250824) 2005; 174 (hep32279-bib-0034-20250824) 2008; 68 (hep32279-bib-0048-20250824) 2017; 545 (hep32279-bib-0040-20250824) 2015; 194 (hep32279-bib-0010-20250824) 2016; 24 (hep32279-bib-0003-20250824) 2018; 68 (hep32279-bib-0005-20250824) 2020; 47 (hep32279-bib-0037-20250824) 2008; 180 (hep32279-bib-0019-20250824) 2020; 158 (hep32279-bib-0007-20250824) 2018; 33 (hep32279-bib-0015-20250824) 2016; 30 (hep32279-bib-0029-20250824) 2008; 329 (hep32279-bib-0013-20250824) 2020; 58 (hep32279-bib-0021-20250824) 2008; 129 (hep32279-bib-0042-20250824) 2017; 25 (hep32279-bib-0011-20250824) 2018; 9 (hep32279-bib-0004-20250824) 2018; 379 (hep32279-bib-0025-20250824) 2017; 6 (hep32279-bib-0022-20250824) 2009; 378 (hep32279-bib-0009-20250824) 2015; 21 (hep32279-bib-0024-20250824) 2020; 26 |
| References_xml | – volume: 3 start-page: 368 year: 2015 end-page: 79 article-title: Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell Fas–FasL‐dependent AICD publication-title: Cancer Immunol Res – volume: 194 start-page: 911 year: 2015 end-page: 20 article-title: Target antigen density governs the efficacy of anti‐CD20‐CD28‐CD3 zeta chimeric antigen receptor‐modified effector CD8+ T cells publication-title: J Immunol – volume: 19 start-page: 3153 year: 2013 end-page: 64 article-title: Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1‐specific chimeric antigen receptor T cells publication-title: Clin Cancer Res – volume: 68 start-page: 574 year: 2018 end-page: 89 article-title: Identification of alpha‐fetoprotein‐specific T‐cell receptors for hepatocellular carcinoma immunotherapy publication-title: Hepatology – volume: 17 start-page: 1206 year: 2010 end-page: 13 article-title: Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off‐target’ activation and unintended initiation of an innate immune response publication-title: Gene Ther – volume: 25 start-page: 1341 year: 2019 end-page: 55 article-title: Clinical lessons learned from the first leg of the CAR T cell journey publication-title: Nat Med – volume: 180 start-page: 7028 year: 2008 end-page: 38 article-title: Antigen sensitivity of CD22‐specific chimeric TCR is modulated by target epitope distance from the cell membrane publication-title: J Immunol – volume: 30 start-page: 1355 year: 2016 end-page: 64 article-title: High‐affinity FRβ‐specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity publication-title: Leukemia – volume: 329 start-page: 112 year: 2008 end-page: 24 article-title: Efficient generation of monoclonal antibodies from single human B cells by single cell RT‐PCR and expression vector cloning publication-title: J Immunol Methods – volume: 369 start-page: 650 year: 2020 end-page: 5 article-title: A neutralizing human antibody binds to the N‐terminal domain of the Spike protein of SARS‐CoV‐2 publication-title: Science – volume: 4 start-page: 592 year: 2012 end-page: 9 article-title: High‐affinity monoclonal antibodies to cell surface tumor antigen glypican‐3 generated through a combination of peptide immunization and flow cytometry screening publication-title: MAbs – volume: 178 start-page: 4650 year: 2007 end-page: 7 article-title: T cell activation by antibody‐like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells publication-title: J Immunol – volume: 25 start-page: 4014 year: 2019 end-page: 25 article-title: Combined CD28 and 4–1BB costimulation potentiates affinity‐tuned chimeric antigen receptor‐engineered T cells publication-title: Clin Cancer Res – volume: 25 start-page: 1408 year: 2019 end-page: 14 article-title: Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low‐affinity CD19 CAR publication-title: Nat Med – volume: 13 year: 2021 article-title: SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models publication-title: Sci Transl Med – volume: 20 start-page: 6418 year: 2014 end-page: 28 article-title: Development of T cells redirected to glypican‐3 for the treatment of hepatocellular carcinoma publication-title: Clin Cancer Res – volume: 12 start-page: 492 year: 2011 end-page: 499 article-title: T cell exhaustion publication-title: Nat Immunol – volume: 59 start-page: 1448 year: 2014 end-page: 58 article-title: Epitope‐optimized alpha‐fetoprotein genetic vaccines prevent carcinogen‐induced murine autochthonous hepatocellular carcinoma publication-title: Hepatology – volume: 47 start-page: 1 year: 2020 end-page: 15 article-title: Engineering T cells for immunotherapy of primary human hepatocellular carcinoma publication-title: J Genet Genomics – volume: 7 start-page: 14366 year: 2017 article-title: Micromolar affinity CAR T cells to ICAM‐1 achieves rapid tumor elimination while avoiding systemic toxicity publication-title: Sci Rep – volume: 6 year: 2017 article-title: Bispecific antibody does not induce T‐cell death mediated by chimeric antigen receptor against disialoganglioside GD2 publication-title: Oncoimmunology – volume: 75 start-page: 3596 year: 2015 end-page: 607 article-title: Affinity‐tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice publication-title: Cancer Res – volume: 174 start-page: 3808 year: 2005 end-page: 17 article-title: Immunization with lentiviral vector‐transduced dendritic cells induces strong and long‐lasting T cell responses and therapeutic immunity publication-title: J Immunol – volume: 21 start-page: 581 year: 2015 end-page: 90 article-title: 4–1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors publication-title: Nat Med – volume: 71 start-page: 209 year: 2021 end-page: 49 article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J Clin – volume: 129 start-page: 899 year: 2008 end-page: 906 article-title: Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4387 tissue samples publication-title: Am J Clin Pathol – volume: 68 start-page: 9832 year: 2008 end-page: 8 article-title: Anti‐glypican 3 antibody as a potential antitumor agent for human liver cancer publication-title: Cancer Res – volume: 372 year: 2021 article-title: Transient rest restores functionality in exhausted CAR‐T cells through epigenetic remodeling publication-title: Science – volume: 22 start-page: 275 year: 2016 end-page: 83 article-title: Glypican‐3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma publication-title: World J Gastroenterol – volume: 43 start-page: D413 year: 2015 end-page: 22 article-title: IMGT(R), the international ImMunoGeneTics information system(R) 25 years on publication-title: Nucleic Acids Res – volume: 26 start-page: 2444 year: 2020 end-page: 51 article-title: Enhancing chimeric antigen receptor T‐cell efficacy in solid tumors publication-title: Clin Cancer Res – volume: 24 start-page: 1135 year: 2016 end-page: 49 article-title: GD2‐specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation‐induced cell death by PD‐1 blockade publication-title: Mol Ther – volume: 379 start-page: 64 year: 2018 end-page: 73 article-title: Chimeric antigen receptor therapy publication-title: N Engl J Med – volume: 18 start-page: 1591 year: 2005 end-page: 8 article-title: The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma publication-title: Mod Pathol – volume: 33 start-page: 547 year: 2018 end-page: 62 article-title: T cell dysfunction in cancer publication-title: Cancer Cell – volume: 11 start-page: 4166 year: 2020 article-title: Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function publication-title: Nat Commun – volume: 25 start-page: 1933 year: 2017 end-page: 45 article-title: Balance of anti‐CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia publication-title: Mol Ther – volume: 21 start-page: 482 year: 2015 end-page: 91 article-title: Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system publication-title: Trends Mol Med – volume: 378 start-page: 279 year: 2009 end-page: 84 article-title: Anti‐glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells publication-title: Biochem Biophys Res Commun – volume: 18 start-page: 295 year: 2020 article-title: 32A9, a novel human antibody for designing an immunotoxin and CAR‐T cells against glypican‐3 in hepatocellular carcinoma publication-title: J Transl Med – volume: 6 start-page: 36 year: 2018 end-page: 46 article-title: High‐affinity GD2‐specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model publication-title: Cancer Immunol Res – volume: 158 start-page: 2250 year: 2020 end-page: 65.e2220 article-title: Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice publication-title: Gastroenterology – volume: 8 start-page: 1597 year: 2017 article-title: PD‐1/PD‐L1 blockade: have we found the key to unleash the antitumor immune response? publication-title: Front Immunol – volume: 9 start-page: 282 year: 2018 article-title: CAR‐T cells: the long and winding road to solid tumors publication-title: Cell Death Dis – volume: 58 start-page: 102931 year: 2020 article-title: CAR‐T design: elements and their synergistic function publication-title: EBioMedicine – volume: 26 start-page: 3979 year: 2020 end-page: 3989 article-title: Chimeric antigen receptor‐glypican‐3 T‐cell therapy for advanced hepatocellular carcinoma: results of phase I trials publication-title: Clin Cancer Res – volume: 6 start-page: 6536 year: 2015 article-title: Immunotoxin targeting glypican‐3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis publication-title: Nat Commun – volume: 545 start-page: 452 year: 2017 end-page: 6 article-title: Chromatin states define tumour‐specific T cell dysfunction and reprogramming publication-title: Nature – volume: 22 start-page: 275 year: 2016 ident: hep32279-bib-0035-20250824 article-title: Glypican‐3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma publication-title: World J Gastroenterol doi: 10.3748/wjg.v22.i1.275 – volume: 8 start-page: 1597 year: 2017 ident: hep32279-bib-0047-20250824 article-title: PD‐1/PD‐L1 blockade: have we found the key to unleash the antitumor immune response? publication-title: Front Immunol doi: 10.3389/fimmu.2017.01597 – volume: 68 start-page: 574 year: 2018 ident: hep32279-bib-0003-20250824 article-title: Identification of alpha‐fetoprotein‐specific T‐cell receptors for hepatocellular carcinoma immunotherapy publication-title: Hepatology doi: 10.1002/hep.29844 – volume: 180 start-page: 7028 year: 2008 ident: hep32279-bib-0037-20250824 article-title: Antigen sensitivity of CD22‐specific chimeric TCR is modulated by target epitope distance from the cell membrane publication-title: J Immunol doi: 10.4049/jimmunol.180.10.7028 – volume: 25 start-page: 4014 year: 2019 ident: hep32279-bib-0038-20250824 article-title: Combined CD28 and 4–1BB costimulation potentiates affinity‐tuned chimeric antigen receptor‐engineered T cells publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-18-2559 – volume: 47 start-page: 1 year: 2020 ident: hep32279-bib-0005-20250824 article-title: Engineering T cells for immunotherapy of primary human hepatocellular carcinoma publication-title: J Genet Genomics doi: 10.1016/j.jgg.2020.01.002 – volume: 3 start-page: 368 year: 2015 ident: hep32279-bib-0043-20250824 article-title: Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell Fas–FasL‐dependent AICD publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-14-0200 – volume: 19 start-page: 3153 year: 2013 ident: hep32279-bib-0014-20250824 article-title: Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1‐specific chimeric antigen receptor T cells publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-0330 – volume: 21 start-page: 482 year: 2015 ident: hep32279-bib-0002-20250824 article-title: Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system publication-title: Trends Mol Med doi: 10.1016/j.molmed.2015.05.005 – volume: 75 start-page: 3596 year: 2015 ident: hep32279-bib-0026-20250824 article-title: Affinity‐tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-15-0159 – volume: 24 start-page: 1135 year: 2016 ident: hep32279-bib-0010-20250824 article-title: GD2‐specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation‐induced cell death by PD‐1 blockade publication-title: Mol Ther doi: 10.1038/mt.2016.63 – volume: 25 start-page: 1341 year: 2019 ident: hep32279-bib-0012-20250824 article-title: Clinical lessons learned from the first leg of the CAR T cell journey publication-title: Nat Med doi: 10.1038/s41591-019-0564-6 – volume: 18 start-page: 1591 year: 2005 ident: hep32279-bib-0041-20250824 article-title: The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma publication-title: Mod Pathol doi: 10.1038/modpathol.3800436 – volume: 13 year: 2021 ident: hep32279-bib-0044-20250824 article-title: SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models publication-title: Sci Transl Med – volume: 329 start-page: 112 year: 2008 ident: hep32279-bib-0029-20250824 article-title: Efficient generation of monoclonal antibodies from single human B cells by single cell RT‐PCR and expression vector cloning publication-title: J Immunol Methods doi: 10.1016/j.jim.2007.09.017 – volume: 379 start-page: 64 year: 2018 ident: hep32279-bib-0004-20250824 article-title: Chimeric antigen receptor therapy publication-title: N Engl J Med doi: 10.1056/NEJMra1706169 – volume: 369 start-page: 650 year: 2020 ident: hep32279-bib-0030-20250824 article-title: A neutralizing human antibody binds to the N‐terminal domain of the Spike protein of SARS‐CoV‐2 publication-title: Science doi: 10.1126/science.abc6952 – volume: 33 start-page: 547 year: 2018 ident: hep32279-bib-0007-20250824 article-title: T cell dysfunction in cancer publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.03.012 – volume: 20 start-page: 6418 year: 2014 ident: hep32279-bib-0018-20250824 article-title: Development of T cells redirected to glypican‐3 for the treatment of hepatocellular carcinoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-1170 – volume: 68 start-page: 9832 year: 2008 ident: hep32279-bib-0034-20250824 article-title: Anti‐glypican 3 antibody as a potential antitumor agent for human liver cancer publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-1973 – volume: 21 start-page: 581 year: 2015 ident: hep32279-bib-0009-20250824 article-title: 4–1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors publication-title: Nat Med doi: 10.1038/nm.3838 – volume: 26 start-page: 3979 year: 2020 ident: hep32279-bib-0024-20250824 article-title: Chimeric antigen receptor‐glypican‐3 T‐cell therapy for advanced hepatocellular carcinoma: results of phase I trials publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-3259 – volume: 43 start-page: D413 year: 2015 ident: hep32279-bib-0033-20250824 article-title: IMGT(R), the international ImMunoGeneTics information system(R) 25 years on publication-title: Nucleic Acids Res doi: 10.1093/nar/gku1056 – volume: 18 start-page: 295 year: 2020 ident: hep32279-bib-0020-20250824 article-title: 32A9, a novel human antibody for designing an immunotoxin and CAR‐T cells against glypican‐3 in hepatocellular carcinoma publication-title: J Transl Med doi: 10.1186/s12967-020-02462-1 – volume: 174 start-page: 3808 year: 2005 ident: hep32279-bib-0031-20250824 article-title: Immunization with lentiviral vector‐transduced dendritic cells induces strong and long‐lasting T cell responses and therapeutic immunity publication-title: J Immunol doi: 10.4049/jimmunol.174.6.3808 – volume: 25 start-page: 1933 year: 2017 ident: hep32279-bib-0042-20250824 article-title: Balance of anti‐CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia publication-title: Mol Ther doi: 10.1016/j.ymthe.2017.04.017 – volume: 545 start-page: 452 year: 2017 ident: hep32279-bib-0048-20250824 article-title: Chromatin states define tumour‐specific T cell dysfunction and reprogramming publication-title: Nature doi: 10.1038/nature22367 – volume: 4 start-page: 592 year: 2012 ident: hep32279-bib-0023-20250824 article-title: High‐affinity monoclonal antibodies to cell surface tumor antigen glypican‐3 generated through a combination of peptide immunization and flow cytometry screening publication-title: MAbs doi: 10.4161/mabs.20933 – volume: 59 start-page: 1448 year: 2014 ident: hep32279-bib-0032-20250824 article-title: Epitope‐optimized alpha‐fetoprotein genetic vaccines prevent carcinogen‐induced murine autochthonous hepatocellular carcinoma publication-title: Hepatology doi: 10.1002/hep.26893 – volume: 378 start-page: 279 year: 2009 ident: hep32279-bib-0022-20250824 article-title: Anti‐glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2008.11.033 – volume: 7 start-page: 14366 year: 2017 ident: hep32279-bib-0027-20250824 article-title: Micromolar affinity CAR T cells to ICAM‐1 achieves rapid tumor elimination while avoiding systemic toxicity publication-title: Sci Rep doi: 10.1038/s41598-017-14749-3 – volume: 194 start-page: 911 year: 2015 ident: hep32279-bib-0040-20250824 article-title: Target antigen density governs the efficacy of anti‐CD20‐CD28‐CD3 zeta chimeric antigen receptor‐modified effector CD8+ T cells publication-title: J Immunol doi: 10.4049/jimmunol.1402346 – volume: 58 start-page: 102931 year: 2020 ident: hep32279-bib-0013-20250824 article-title: CAR‐T design: elements and their synergistic function publication-title: EBioMedicine doi: 10.1016/j.ebiom.2020.102931 – volume: 12 start-page: 492 year: 2011 ident: hep32279-bib-0006-20250824 article-title: T cell exhaustion publication-title: Nat Immunol doi: 10.1038/ni.2035 – volume: 129 start-page: 899 year: 2008 ident: hep32279-bib-0021-20250824 article-title: Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4387 tissue samples publication-title: Am J Clin Pathol doi: 10.1309/HCQWPWD50XHD2DW6 – volume: 26 start-page: 2444 year: 2020 ident: hep32279-bib-0046-20250824 article-title: Enhancing chimeric antigen receptor T‐cell efficacy in solid tumors publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-1835 – volume: 158 start-page: 2250 year: 2020 ident: hep32279-bib-0019-20250824 article-title: Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.02.011 – volume: 11 start-page: 4166 year: 2020 ident: hep32279-bib-0028-20250824 article-title: Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function publication-title: Nat Commun doi: 10.1038/s41467-020-17970-3 – volume: 178 start-page: 4650 year: 2007 ident: hep32279-bib-0036-20250824 article-title: T cell activation by antibody‐like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells publication-title: J Immunol doi: 10.4049/jimmunol.178.7.4650 – volume: 372 year: 2021 ident: hep32279-bib-0045-20250824 article-title: Transient rest restores functionality in exhausted CAR‐T cells through epigenetic remodeling publication-title: Science – volume: 6 start-page: 6536 year: 2015 ident: hep32279-bib-0039-20250824 article-title: Immunotoxin targeting glypican‐3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis publication-title: Nat Commun doi: 10.1038/ncomms7536 – volume: 6 start-page: 36 year: 2018 ident: hep32279-bib-0016-20250824 article-title: High‐affinity GD2‐specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-17-0211 – volume: 25 start-page: 1408 year: 2019 ident: hep32279-bib-0017-20250824 article-title: Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low‐affinity CD19 CAR publication-title: Nat Med doi: 10.1038/s41591-019-0549-5 – volume: 9 start-page: 282 year: 2018 ident: hep32279-bib-0011-20250824 article-title: CAR‐T cells: the long and winding road to solid tumors publication-title: Cell Death Dis doi: 10.1038/s41419-018-0278-6 – volume: 6 year: 2017 ident: hep32279-bib-0025-20250824 article-title: Bispecific antibody does not induce T‐cell death mediated by chimeric antigen receptor against disialoganglioside GD2 publication-title: Oncoimmunology – volume: 71 start-page: 209 year: 2021 ident: hep32279-bib-0001-20250824 article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J Clin – volume: 17 start-page: 1206 year: 2010 ident: hep32279-bib-0008-20250824 article-title: Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off‐target’ activation and unintended initiation of an innate immune response publication-title: Gene Ther doi: 10.1038/gt.2010.91 – volume: 30 start-page: 1355 year: 2016 ident: hep32279-bib-0015-20250824 article-title: High‐affinity FRβ‐specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity publication-title: Leukemia doi: 10.1038/leu.2016.35 |
| SSID | ssj0009428 |
| Score | 2.4958951 |
| Snippet | Background and Aims
Chimeric antigen receptor engineered T cells (CARTs) for HCC and other solid tumors are not as effective as they are for blood cancers.... Chimeric antigen receptor engineered T cells (CARTs) for HCC and other solid tumors are not as effective as they are for blood cancers. CARTs may lose function... Background and AimsChimeric antigen receptor engineered T cells (CARTs) for HCC and other solid tumors are not as effective as they are for blood cancers.... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 330 |
| SubjectTerms | Affinity Antigens Antitumor activity Apoptosis Avidity Blood cancer Chimeric antigen receptors Epitopes Hematological diseases Heparan sulfate proteoglycans Hepatology Lymphocytes T Monoclonal antibodies Solid tumors Tumor cells Tumor-infiltrating lymphocytes Tumors Xenografts |
| Title | Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.32279 https://www.ncbi.nlm.nih.gov/pubmed/34897774 https://www.proquest.com/docview/2690094547 https://www.proquest.com/docview/2609457312 https://pubmed.ncbi.nlm.nih.gov/PMC10568540 |
| Volume | 76 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VPSAuvB-BggziwCWt1_E6sTihVasVUiuEqNQDUmQ7drdiSap98DrxE_iN_BJmnEdZChLiFjmTxI8Z-5t45jPAMyEM4gpZpZqrkEpTjFJd6JByF7R0niAFOYqHR2p6LF-djE-24EWfC9PyQww_3Mgy4nxNBm7scu-CNHTm0WEn_jucfylWiwDRmwvqKC3juarodXHaXdY9qxAXe8OTm2vRJYB5OU7yV_waF6CD6_Cur3obd_J-d72yu-7rb6yO_9m2G3CtA6bsZatJN2HL17fgymG39X4blkfNRz9n8-bTj2_fKRAe4Ts7nX85p3kUizJGSZsUeMQmCJKXDP14VCHmP8-IWgiHn5m6YjFTZeVZtV5Q0haWUazCh2bBusgSZk7NGWJWNp1M7sDxwf7byTTtTmxIHXo-Oh1pm-NiV6hK6OC8UGNjVGGkG9lCBPSWrHHECcDRn5euMiHP86B4yLzihnOT3YXtuqn9fWACoWBmCylCyCS-zyhtq9y7ES4uVnKbwPN-7ErX0ZnTqRrzsiViFiV2Yhk7MYGng-h5y-HxJ6GdXgHKzoyXpVCaNGks8wSeDLfRAGlXxdS-WZMMSeTZSCRwr9WX4SsZdgo2USZQbGjSIEDk3pt36rNZJPlG3KsKhNPYzqgpf695Od1_HS8e_LvoQ7gqKI8jRjLuwPZqsfaPEF2t7ONoRj8Bnpsj1w |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKkYALb2iggEEcuKR1HK8TS1zQ0ipAd4VQK_WCIsexuxXbpNoHrxM_gd_IL2HGeZSlICFukTNJbGfG_sae-UzIU8414ApRhopJFwqdRqFKlQuZcUoYi5ACHcXRWGYH4vXh4HCNPO9yYRp-iH7BDS3Dj9do4LggvX3GGjqx4LEjAd4FchFP9Ebm_JfvzsijlPAnq4LfxXB_WXW8Qoxv94-uzkbnIOb5SMlfEayfgnavkfdd5ZvIkw9by0WxZb7-xuv4v627Tq622JS-aJTpBlmz1U1yadTuvt8i83H90U7ptP7049t3jIUHBE-Ppl9OcSiFophi3ibGHtEh4OQ5BVcetIjazxNkFwINoLoqqU9WWVhaLmeYtwVlGK5wUs9oG1xC9ZE-BthKs-HwNjnY3dkfZmF7aENowPlRYaSKBOa7VJZcOWO5HGgtUy1MVKTcgcNUaIO0AAxcemFK7ZIkcZK52EqmGdPxHbJe1ZXdIJQDGoyLVHDnYgHv01IVZWJNBPNLIVgRkGfdz8tNy2iOB2tM84aLmefQibnvxIA86UVPGxqPPwltdhqQt5Y8z7lUqEoDkQTkcX8bbBA3VnRl6yXKoEQSRzwgdxuF6b8SQ6dAE0VA0hVV6gWQ33v1TnU88TzfAH1lCoga2ulV5e81z7Odt_7i3r-LPiKXs_3RXr73avzmPrnCMa3DBzZukvXFbGkfANhaFA-9Tf0Es9cn8w |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwEB6VIlW8cB-BAgbxwEtar-N1YvGEtl0tR1cVolIfkCLHsbsVS7Lag-uJn8Bv5Jcwk6ssBQnxFjmTxMeM_U088xngiRAGcYXMQ82VD6VJeqFOtA-59VpaR5CCHMWDsRodyZfH_eMNeNbmwtT8EN0PN7KMar4mA5_lfveMNHTi0GEn_rsLcFEqrunchr03Z9xRWlYHq6LbxWl7Wbe0Qlzsdo-uL0bnEOb5QMlfAWy1Ag2vwLu27nXgyfud1TLbsV9_o3X8z8ZdhcsNMmXPa1W6BhuuuA5bB83e-w1YjMuPbsqm5acf375TJDzid3Yy_TKjiRSLIkZZmxR5xAaIkhcMHXnUIeY-T4hbCMefmSJnVarK0rF8NaesLSyjYIUP5Zw1oSXMnJhTBK1sNBjchKPh_tvBKGyObAgtuj467OksxtUuUbnQ3jqh-saoxEjbyxLh0V3KjCVSAI4OvbS58XEce8V95BQ3nJvoFmwWZeHuABOIBaMskcL7SOL7jNJZHjvbw9UlkzwL4Gk7dqlt-MzpWI1pWjMxixQ7Ma06MYDHneisJvH4k9B2qwBpY8eLVChNmtSXcQCPuttogbStYgpXrkiGJOKoJwK4XetL95UIOwWbKANI1jSpEyB27_U7xemkYvlG4KsSxNPYzkpT_l7zdLR_WF3c_XfRh7B1uDdMX78Yv7oHlwTldFRRjduwuZyv3H1EWsvsQWVRPwEsuSai |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Novel+low-avidity+glypican-3+specific+CARTs+resist+exhaustion+and+mediate+durable+antitumor+effects+against+HCC&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Caraballo+Galva%2C+Leidy+D.&rft.au=Jiang%2C+Xiaotao&rft.au=Hussein%2C+Mohamed+S.&rft.au=Zhang%2C+Huajun&rft.date=2022-08-01&rft.issn=0270-9139&rft.eissn=1527-3350&rft.volume=76&rft.issue=2&rft.spage=330&rft.epage=344&rft_id=info:doi/10.1002%2Fhep.32279&rft_id=info%3Apmid%2F34897774&rft.externalDocID=PMC10568540 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon |